131 related articles for article (PubMed ID: 38484940)
1. Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1
Jia X; Li Z; Zhou R; Feng W; Yi L; Zhang H; Chen B; Li Q; Huang S; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167123. PubMed ID: 38484940
[TBL] [Abstract][Full Text] [Related]
2. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer.
Li X; Sun Z; Peng G; Xiao Y; Guo J; Wu B; Li X; Zhou W; Li J; Li Z; Bai C; Zhao L; Han Q; Zhao RC; Wang X
Theranostics; 2022; 12(2):620-638. PubMed ID: 34976204
[No Abstract] [Full Text] [Related]
3. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
4. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of cancer-associated fibroblast signature in gastric cancer.
Zhao Z; Mak TK; Shi Y; Li K; Huo M; Zhang C
Heliyon; 2023 Sep; 9(9):e19217. PubMed ID: 37809716
[TBL] [Abstract][Full Text] [Related]
6. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer.
Zhou Z; Guo S; Lai S; Wang T; Du Y; Deng J; Zhang S; Gao G; Zhang J
BMC Cancer; 2023 Jan; 23(1):108. PubMed ID: 36717783
[TBL] [Abstract][Full Text] [Related]
7. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.
Sang Q; Dai W; Yu J; Chen Y; Fan Z; Liu J; Li F; Li J; Wu X; Hou J; Yu B; Feng H; Zhu ZG; Su L; Li YY; Liu B
Front Immunol; 2022; 13():983632. PubMed ID: 36032070
[TBL] [Abstract][Full Text] [Related]
9. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
10. Development of cancer-associated fibroblasts subtype and prognostic model in gastric cancer and the landscape of tumor microenvironment.
Zhang C; Sun D; Li C; Liu Y; Zhou Y; Zhang J
Int J Biochem Cell Biol; 2022 Nov; 152():106309. PubMed ID: 36174922
[TBL] [Abstract][Full Text] [Related]
11. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
Liu W; Wang M; Wang M; Liu M
Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
[TBL] [Abstract][Full Text] [Related]
12. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
13. Integrated transcriptomic analysis systematically reveals the heterogeneity and molecular characterization of cancer-associated fibroblasts in osteosarcoma.
Liu Y; Han X; Han Y; Bi J; Wu Y; Xiang D; Zhang Y; Bi W; Xu M; Li J
Gene; 2024 May; 907():148286. PubMed ID: 38367852
[TBL] [Abstract][Full Text] [Related]
14. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer.
Ham IH; Oh HJ; Jin H; Bae CA; Jeon SM; Choi KS; Son SY; Han SU; Brekken RA; Lee D; Hur H
Mol Cancer; 2019 Mar; 18(1):68. PubMed ID: 30927911
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analyses of the cancer-associated fibroblast subtypes and their score system for prediction of outcomes and immunosuppressive microenvironment in prostate cancer.
Gao Z; Zhang N; An B; Li D; Fang Z; Xu D
Cancer Cell Int; 2024 Apr; 24(1):127. PubMed ID: 38580966
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response.
Chen Y; Sun Z; Wan L; Chen H; Xi T; Jiang Y
Front Immunol; 2022; 13():890922. PubMed ID: 35572498
[TBL] [Abstract][Full Text] [Related]
18. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.
Galbo PM; Zang X; Zheng D
Clin Cancer Res; 2021 May; 27(9):2636-2647. PubMed ID: 33622705
[TBL] [Abstract][Full Text] [Related]
19. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.
Liu Z; Sun L; Peng X; Zhu J; Wu C; Zhu W; Huang C; Zhu Z
Apoptosis; 2024 Jun; 29(5-6):799-815. PubMed ID: 38347337
[TBL] [Abstract][Full Text] [Related]
20. Five EMT-related genes signature predicts overall survival and immune environment in microsatellite instability-high gastric cancer.
Zhang M; Cao C; Li X; Gu Q; Xu Y; Zhu Z; Xu D; Wei S; Chen H; Yang Y; Gao H; Yu L; Li J
Cancer Med; 2023 Jan; 12(2):2075-2088. PubMed ID: 35789544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
